Acid Sphingomyelinase Deficiency (ASMD) Clinical Trials

Find Acid Sphingomyelinase Deficiency (ASMD) Clinical Trials Near You

Niemann-PID: Study of the Prevalence of Acid Sphingomyelinase Deficiency/Niemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this clinical trial is to optimise and facilitate screening for Acid SphingoMyelinase Deficiency (ASMD) disease, by evaluating acid sphingomyelinase activity and, where appropriate, LysoSM levels in a cohort of 200 participants with diffuse interstitial lund disease (ILD) at risk of developing ASMD disease. ILD is common in the general population, so in order to limit the number of differential diagnoses, the population to be studied will be restricted to participants aged between 15 years and 3 months and 60 years, with ILD plus ground-glass opacities on chest CT scan certified by a pulmonologist/radiologist or internist, AND splenomegaly or splenectomy, and/or thrombocytopenia, and/or low HDL cholesterol, and/or parental consanguinity which increase the sensitivity of ASMD screening. In this clinical trail, two procedures are added, participants will be asked for : * a blood sample to measure the acid sphingomyelinase enzyme activity and LysoSM, if required. * a follow-up visit at 6 months

Eligibility
Participation Requirements
Sex: All
Minimum Age: 15
Maximum Age: 60
Healthy Volunteers: f
View:

• Interstitial lung disease with ground-glass lesions on a chest CT scan certified by a pneumologist/radiologist or internist.

• At least one of the following criteria :

‣ Splenomegaly (palpable spleen or craniocaudal length ≥ 13 cm)

⁃ Splenectomy

⁃ Thrombocytopenia (platelets \< 150 G/L)

⁃ Low HDL-cholesterol (\<0.4 g/l or 1.03 mmol/l)

⁃ Notion of parental consanguinity

• Have given their written informed consent, in accordance with regulations.

• Affiliated to the social security system or entitled beneficiary (excluding AME).

Locations
Other Locations
France
Groupe Hospitalier Diaconesses Croix Saint-Simon
RECRUITING
Paris
Contact Information
Primary
Djazia BOUZELMAT Clinical Research Assistant
dbouzelmat@hopital-dcss.org
+ 33 01 44 64 30 98
Time Frame
Start Date: 2025-06-05
Estimated Completion Date: 2029-03-01
Participants
Target number of participants: 200
Treatments
Experimental: Experimental Cohort
The participants will be asked for a :~1. Venous blood collection (4ml EDTA tube) for the determination of :~ * acid sphingomyelinase enzyme activity in all participants included in the study. The determination of acid sphigomyelinase enzyme activity will be performed using a multiplex blotting assay that allows simultaneous determination of acid sphigomyelinase activity (ASMD) by tandem MS/MS mass spectrometry, but also Beta-glucocerebrosidase (Gaucher disease), alpha-galactosidase (Fabry disease), Maltase Acid (Pompe disease), Galactocerebrosidase (Krabbe disease), Alpha-L iduronidase (control enzyme) (MPSI)).~ * if acid sphingomyelinase activity \< 1.82 μmol/h/l (decreased) is detected, the concentration of lysoSM should be determined on the same sample.~2. Appropriate participant care management in the event of a positive ASMD screening.
Sponsors
Collaborators: University Hospital, Marseille, Bichat Hospital, Hospices Civils de Lyon, Bicetre Hospital, Rennes University Hospital, Centre Hospitalier Universitaire Dijon, University Hospital, Lille, Hospital Avicenne, Tenon Hospital, Paris
Leads: Wladimir MAUHIN, Dr

This content was sourced from clinicaltrials.gov